Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma

Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma

Glioblastoma (GBM) is resistant to most multimodal therapies. Clinical success of immune-checkpoint inhibitors (ICIs) has spurred interest in applying ICIs targeting CTLA4, PD1 or IDO1 against GBM. This amplifies the need to ascertain GBM's intrinsic susceptibility (or resistance) toward these...

Full description

Bibliographic Details
Main Authors: Abhishek D. Garg, Lien Vandenberk, Matthias Van Woensel, Jochen Belmans, Marco Schaaf, Louis Boon, Steven De Vleeschouwer, Patrizia Agostinis
Format: Article
Language:English
Published: Taylor & Francis Group 2017-04-01
Series:OncoImmunology
Subjects:
cancer immunotherapy
copy-number alterations (cna)
ctla4
high-grade glioma
ido1
immune-checkpoint blockers (icbs)
mutational burden
neoantigen
patient prognosis
pd1
t cells
treg cells
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1295903

Internet

http://dx.doi.org/10.1080/2162402X.2017.1295903

Similar Items